CHILDREN'S ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1998.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
Children's Advil is an oral chewable tablet formulation of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce pain and inflammation. It is indicated for fever and pain relief in pediatric patients. The product has been marketed since 1998 and remains a widely recognized over-the-counter pain reliever for children.
As a mature OTC product approaching loss of exclusivity, the brand team is likely focused on defending market share against generic and competitive alternatives in a commoditized pediatric pain/fever category.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on CHILDREN'S ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Children's Advil provides exposure to OTC marketing, consumer brand management, and retail strategy in a mature product category. Opportunities focus on defending market share, optimizing profitability, and supporting line extensions rather than growth-stage innovation.